Brief: Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
11/05/2026 14:28
May 11 (Reuters) - Longeveron Inc LGVN.O: LONGEVERON ANNOUNCES INDEPENDENT DATA MONITORING COMMITTEE POSITIVE REVIEW AND RECOMMENDATION TO COMPLETE PHASE 2B STEM CELL THERAPY CLINICAL TRIAL IN HYPOPLASTIC LEFT HEART SYNDROME (HLHS) LONGEVERON INC - DMC FINDS NO SAFETY CONCERNS, RECOMMENDS PHASE 2B TRIAL CONTINUE TO COMPLETION LONGEVERON INC - TOP-LINE RESULTS FROM ELPIS II TRIAL ANTICIPATED IN AUGUST 2026 Source text: ID:nGNXZJ6w7 Further company coverage: LGVN.O ((Reuters.Briefs@thomsonreuters.com;))